BiotechTube

Placebo + YH14618

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Disc Degenerative Disease

Conditions

Disc Degenerative Disease

Trial Timeline

Mar 1, 2015 → Aug 1, 2016

NCT ID
NCT02320019

About Placebo + YH14618

Placebo + YH14618 is a phase 2 stage product being developed by Yuhan for Disc Degenerative Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02320019. Target conditions include Disc Degenerative Disease.

What happened to similar drugs?

0 of 3 similar drugs in Disc Degenerative Disease were approved

Approved (0) Terminated (0) Active (3)
🔄Rexlemestrocel-L + HA mixture + SalineMesoblastPhase 3
🔄Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + PlaceboMesoblastPhase 3
🔄Processed Nerve Allograft (human)AxogenPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02320019Phase 2Completed

Competing Products

20 competing products in Disc Degenerative Disease

See all competitors
ProductCompanyStageHype Score
YH14618 + YH14618 + YH14618 + PlaceboYuhanPhase 1/2
32
SecukinumabNovartisPhase 2
27
Placebo + DaxdilimabAmgenPhase 2
27
Tofacitinib citratePfizerPhase 1
21
EtanerceptPfizerPhase 2
35
Deucravacitinib + PlaceboBristol Myers SquibbPhase 2
39
Belimumab 1 mg/kg + Belimumab 10 mg/kgGSK plcPre-clinical
26
RuxolitinibIncytePhase 2
32
Lumbar Interbody Fusion with Autograft + Lumbar Interbody Fusion with NeoFuse + Lumbar Interbody Fusion with NeoFuseMesoblastPhase 2
29
NeoFuseMesoblastPhase 2
29
Rexlemestrocel-L + HA mixture + SalineMesoblastPhase 3
41
Single Dose MPCs Injection + Single Dose MPCs InjectionMesoblastPhase 2
29
Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + PlaceboMesoblastPhase 3
34
NeoFuseMesoblastPhase 1/2
26
NeoFuseMesoblastPhase 1/2
26
PLF with NeoFuse + PLF with NeoFuse + PLF with NeoFuseMesoblastPhase 1/2
18
Processed Nerve Allograft (human)AxogenPhase 3
34
R932333 + PlaceboRigel PharmaceuticalsPhase 2
29
3,4-methylenedioxymethamphetamine or PlaceboPacific BiosciencesPre-clinical
16
Use iliac bone graft + use bone morphogenetic protein + use bone derived allograft MSCs + Use adipose tissue derived MSCs + Use amnion/placental derived MSCsBrain BiotechPhase 2/3
28